Acasti Pharma’s Strategic Moves and Shareholder Decisions
Company Announcements

Acasti Pharma’s Strategic Moves and Shareholder Decisions

Acasti Pharma ( (ACST) ) has shared an announcement.

At a recent shareholder meeting with strong attendance, several key decisions were made affecting the company’s future. Shareholders elected director nominees and appointed KPMG as the independent auditor. Additionally, executive compensation was approved on an advisory basis. The company will undergo a significant transition, moving from Québec to British Columbia, and then further domesticating to Delaware. Finally, the shareholders sanctioned the 2024 Equity Incentive Plan, setting the stage for strategic corporate and financial advancements.

For detailed information about ACST stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAcasti Pharma announces corporate name change to Grace Therapeutics
TheFlyAcasti Pharma price target raised to $8 from $6 at Craig-Hallum
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App